OnabotulinumtoxinA injection to the external urethral sphincter for voiding dysfunction in females: a tertiary centre experience
BAUS ePoster online library. Kocadag H. 06/27/18; 211389; P10-1 Disclosure(s)(s): Nothing to disclose
Dr. Huriye Kocadag
Dr. Huriye Kocadag
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)
Aims: Treatment options for voiding dysfunction in females are limited. The aim of this study was to examine the functional outcomes of onabotulinumtoxinA injections into the external urethral sphincter (EUS) for voiding dysfunction in females.

Methods: A retrospective analysis of a prospective database was performed. Cases were performed from 2015 to 2017. Patients were evaluated with pre-operative videourodynamic study and urethral pressure profilometry.

Results: 10 female patients with mean age 45.5 years (18-80years) were identified. 4 had urodynamic evidence of bladder outflow obstruction (2 had detrusor sphincter dyssynergia), and 6 had an acontractile detrusor. The mean pre-op mid-urethral closure pressure (MUCP) was 93.3cmH20 (mean expected MUCP was 45). 6 had failed previous Sacral Nerve Stimulation. 4 women were voiding pre-onabotulinumtoxinA, 4 were performing clean intermittent self-catheterisation (CISC), and 2 had an indwelling suprapubic catheter (SPC). After onabotulinumtoxinA, 6 were voiding, 2 were performing CISC, and 2 remained with an SPC. Median pre-op QMax improved from 8.5ml/s to 12.5ml/s, and mean post void residual volume decreased from 244mls to 94mls. 4 patients reported quality of life improvement after treatment, however 1 reported short lived benefit lasting less than 3 months. 2 patients went onto repeat treatments. There were no significant adverse events. 1 patient developed transient stress urinary incontinence.

Conclusion: OnabotulinumtoxinA to the EUS, is a valid treatment in females with voiding dysfunction, where therapeutic options are limited. The results can be short lived and patients must be made aware. Further study is required, with longer term follow up.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings